ArticleCell biochemistry and biophysics2025
Salidroside Prevents Keloid Fibroblast Aggressive Progression by Upregulating miR-26a-5p to Inhibit JAG1.
Article in Cell biochemistry and biophysics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- LLLT-ADSCs Curtail the Progression of Keloid Through Exosomal miR-26a-5p Downregulating Jag/Notch Pathway.Lasers in surgery and medicine · 2026Article
- Metabolic reprogramming and ferroptosis in keloid pathogenesis: new insights for targeted therapy.Molecular biology reports · 2026Review
- A panoramic analysis of keloid pathogenesis: multidimensional network regulation of genetics-immunity-metabolism-mechanical force.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Salidroside, a natural herb, exerts considerable anti-tumor effects in various human cancers. Evidence unveils that Salidroside mediates gene expression to affect cancer progression. Our work intended to uncover the molecular mechanism of Salidroside functional role in keloid. Expression analysis for JAG1 and miR-26a-5p in tissues and cells was performed using qRT-PCR or western blotting. For functional analysis, cell proliferation, apoptosis and migration were ascertained by CCK-8, flow cytometry and Transwell assay, respectively. The putative binding relationship between JAG1 and miR-26a-5p was further confirmed by dual-luciferase reporter assay. Salidroside exerted pharmacological properties in keloid and impaired keloid fibroblast (KF) viability. JAG1 was upregulated in keloid tissues, and its expression was repressed by Salidroside in KFs. Salidroside depleted KF proliferation and migration but stimulated apoptosis, and JAG1 knockdown largely strengthened the functional effects of Salidroside. MiR-26a-5p interacted with JAG1 3'UTR and expressed with an opposite pattern with JAG1 in keloid. Inhibition of miR-26a-5p largely abolished the effects of JAG1 knockdown in Salidroside-treated KFs, leading to the recovery of KF aggressive behaviors. Salidroside blocked KF aggressive progression by upregulating miR-26a-5p to inhibit JAG1, which provided evidence on the anti-tumor effects of Salidroside in human keloid.
Indexed as
Identifiers
39825059What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.